HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Infection by Strongyloides stercoralis — Clinical Guidelines

Overview

Strongyloidiasis, caused by the nematode parasite Strongyloides stercoralis, is a neglected tropical disease affecting over 30-100 million individuals globally, primarily in tropical and subtropical regions 1 2 3. This chronic infection can range from asymptomatic to symptomatic forms, with severe complications including hyperinfection syndrome in immunocompromised patients, posing significant morbidity and mortality risks 4 5. Accurate diagnosis remains challenging due to intermittent larval shedding, necessitating the development and implementation of rapid diagnostic tools for effective management and control 6 7. Understanding and addressing strongyloidiasis is crucial for improving public health outcomes, particularly in high-risk populations such as immunocompromised individuals and those in endemic areas 8. 1 Prevalence and Diagnostic Performance of Molecular and Serological Tests for Strongyloides stercoralis Infection in Immunosuppressed Patients from North India. 2 Diagnostic performance of a Strongyloides IgG4 Rapid Test in detecting human Strongyloides stercoralis infection. 3 Circulating Angiopoietin-like proteins in Strongyloides Stercoralis infection and reversal following treatment. 4 Technical evaluation of the InBios Strongy Detect IgG ELISA assay for the diagnosis of Strongyloides stercoralis infection. 5 Evaluation of the SsIR/NIE recombinant antigen ELISA for the follow up of patients infected by Strongyloides stercoralis: a diagnostic study. 6 Seropositivity Rates of Strongyloides stercoralis Antibody in the Southeastern Region of Republic of Korea: A Single-Center Retrospective Study. 7 Strongyloidiasis: A Neglected Tropical Disease. 8 Diagnostic performance of urinary IgG antibody detection: A novel approach for population screening of strongyloidiasis.

Pathophysiology Strongyloides stercoralis infection primarily affects the gastrointestinal tract but can disseminate to other organs, particularly in immunocompromised individuals, leading to severe complications 1 2. The parasite's unique life cycle includes an autoinfective phase within the human host, where rhabditoid larvae (L3) can molt into filariform larvae (F3) capable of penetrating the skin, perpetuating the infection 3. This autoinfection cycle contributes to chronic, often asymptomatic infections that can persist for years, characterized by intermittent release of larvae in feces, which can contaminate soil and reinfect the host 4. In immunocompromised patients, the parasite's reproductive ability escalates dramatically, leading to hyperinfection syndrome characterized by massive larval proliferation and systemic spread 5. Dissemination of larvae can result in disseminated strongyloidiasis, affecting organs such as the lungs, skin, and eyes, causing severe inflammation and tissue damage 6. The immune response to S. stercoralis is predominantly Th2-oriented, marked by elevated levels of cytokines like IL-4, IL-5, and IL-13, which promote eosinophilia and contribute to parasite control but also facilitate the parasite's immunomodulatory strategies 7. Despite this immune response, S. stercoralis employs mechanisms to evade immune detection, including modulation of host immune responses and secretion of molecules that interfere with immune cell function 8. The chronic nature of strongyloidiasis can lead to persistent gastrointestinal symptoms including abdominal pain, diarrhea, and malabsorption due to continuous larval migration and tissue damage within the gut 9. In immunocompromised individuals, the lack of effective immune regulation allows for unchecked larval proliferation, potentially leading to life-threatening complications such as disseminated infection, which can be fatal in up to 85% of cases 10. Early diagnosis and timely treatment are crucial, especially with interventions like ivermectin for hyperinfection and disseminated strongyloidiasis, aiming to mitigate these severe outcomes 11.

Epidemiology

Strongyloidiasis, caused by Strongyloides stercoralis, is a neglected tropical disease with a global prevalence estimated at approximately 300–600 million people 1, primarily affecting tropical and subtropical regions due to inadequate sanitation and poor hygiene conditions 2. In specific high-risk areas such as parts of Africa, Asia, and Latin America, prevalence rates can exceed significant thresholds; for instance, in some regions of Peru, prevalence has been reported up to 70% 3. Within Australia, particularly among Aboriginal and Torres Strait Islander communities, seropositivity rates have been notably high, reaching up to 58% in the Kimberley region in Western Australia in 1986 4. In Korea, while specific seroprevalence data are limited, estimates suggest a broader prevalence potentially ranging from 5–10% across Northeast Asia 5. Regarding demographic distribution, strongyloidiasis disproportionately affects marginalized populations with limited access to healthcare and sanitation facilities 6. Children and immunocompromised individuals, including those with HIV/AIDS or undergoing immunosuppressive therapy, are particularly vulnerable, with up to 85% mortality rates reported in severe cases due to hyperinfection syndrome 7. Globally, while specific age and sex distributions are not uniformly documented, the disease tends to affect all age groups but shows higher clinical manifestations in adults and children under suboptimal health conditions 8. The inclusion of women of reproductive age and high-risk occupational groups in surveillance and treatment programs reflects an expanding target population to address the chronic and often asymptomatic nature of the infection 9. 1 Prevalence and Diagnostic Performance of Molecular and Serological Tests for Strongyloides stercoralis Infection in Immunosuppressed Patients from North India. 2 Recombinant antigen-based lateral flow tests for the detection of Strongyloides stercoralis infection. 3 The infection burden of Strongyloides stercoralis in India remains poorly defined but highlights significant regional disparities. 4 Seropositivity and geographical distribution of Strongyloides stercoralis in Australia: A study of pathology laboratory data from 2012-2016. 5 Seropositivity Rates of Strongyloides stercoralis Antibody in the Southeastern Region of Republic of Korea: A Single-Center Retrospective Study. 6 Technical evaluation of the InBios Strongy Detect IgG ELISA assay for the diagnosis of Strongyloides stercoralis infection. 7 Circulating Angiopoietin-like proteins in Strongyloides stercoralis infection and reversal following treatment. 8 Evaluation of the SsIR/NIE recombinant antigen ELISA for the follow up of patients infected by Strongyloides stercoralis: a diagnostic study. 9 Innovative approaches to improve serodiagnosis of Strongyloides stercoralis infection.

Clinical Presentation Typical Symptoms:

Gastrointestinal Symptoms: Abdominal pain, chronic diarrhea, bloating, and malabsorption are common manifestations 3. These symptoms often persist for years without diagnosis due to the chronic nature of the infection 4.

Skin Manifestations: Pruritus and dermatological manifestations, including eosinophilia, may be observed 5.

Respiratory Symptoms: Pulmonary symptoms such as cough and shortness of breath can occur, particularly in immunocompromised individuals 6. Atypical Symptoms:

Hyperinfection Syndrome: In immunocompromised patients, hyperinfection syndrome can lead to systemic dissemination of larvae, causing fever, weight loss, sepsis, and potentially fatal multi-organ involvement 4. Mortality rates in such cases can exceed 85% 5.

Disseminated Infection: Disseminated strongyloidiasis affecting organs beyond the gastrointestinal tract, including the liver, lungs, and brain, can occur 6. This is particularly concerning in patients undergoing immunosuppressive therapies or with underlying conditions like HIV/AIDS 7. Red-Flag Features:

Recurrent or Persistent Gastrointestinal Symptoms: Persistent abdominal pain, chronic diarrhea lasting more than 3 months, especially in individuals with compromised immune systems 3.

Severe or Unexplained Fever: Fever accompanying other systemic symptoms may indicate hyperinfection syndrome 4.

Significant Weight Loss: Unexplained weight loss exceeding 10% of body weight within a short period should raise suspicion 5.

Presence of Eosinophilia: Elevated eosinophil counts in peripheral blood can be indicative of strongyloidiasis, particularly in immunocompromised patients 6.

Travel History to Endemic Regions: Recent travel to tropical or subtropical regions where strongyloidiasis is endemic increases the likelihood of infection 2. 1 Seropositivity Rates of Strongyloides stercoralis Antibody in the Southeastern Region of Republic of Korea: A Single-Center Retrospective Study.

2 Strong-LAMP Assay Based on a Strongyloides spp.-Derived Partial Sequence in the 18S rRNA as Potential Biomarker for Strongyloidiasis Diagnosis in Human Urine Samples. 3 Diagnostic performance of urinary IgG antibody detection: A novel approach for population screening of strongyloidiasis. 4 Circulating Angiopoietin-like proteins in Strongyloides Stercoralis infection and reversal following treatment. 5 Technical evaluation of the InBios Strongy Detect IgG ELISA assay for the diagnosis of Strongyloides stercoralis infection. 6 Seropositivity and geographical distribution of Strongyloides stercoralis in Australia: A study of pathology laboratory data from 2012-2016. 7 Strongyloidiasis: A Neglected Tropical Disease.

Diagnosis The diagnosis of Strongyloides stercoralis infection relies on a combination of clinical presentation, serological testing, and parasitological methods tailored to the resource availability and clinical context. Here are the key diagnostic approaches: ### Clinical Presentation and Criteria

Chronic Symptoms: Persistent gastrointestinal symptoms such as abdominal pain, diarrhea, and malabsorption should raise suspicion 4.

Autoinfection Indicators: Presence of symptoms despite effective deworming in endemic areas may suggest autoinfection 5.

Immunocompromised Status: Individuals undergoing immunosuppressive therapies or with underlying conditions like HIV should be closely monitored due to the risk of hyperinfection syndrome 6. ### Serological Testing

ELISA Tests: Utilize recombinant antigen-based ELISAs like the SsIR/NIE and Ss-IR based assays for IgG antibody detection 8. Sensitivity varies but generally shows high specificity. - Positive Threshold: Typically, a titer ≥ 10 arbitrary units (AU) or ≥ 2 standard deviations above the mean for healthy controls is considered positive 8.

Rapid Tests: The Strongyloides IgG4 Rapid Test can be used for point-of-care diagnosis 2. - Positive Threshold: A visible line within 20 minutes post-treatment indicates a positive result 2. ### Parasitological Methods

Fecal Examination: - Baermann Method: Concentrated stool samples should be examined using the Baermann technique for detection of rhabditiform larvae 6. - Detection Sensitivity: Positive if larvae are observed in concentrated stool samples 6. - Agar Plate Culture (APC): Culturing larvae from stool samples on agar plates can enhance sensitivity 6. - Positive Threshold: Identification of Strongyloides larvae within 7-10 days post-inoculation 6. - Quantitative Fecal Egg Count (QFEC): Useful for monitoring treatment efficacy but less sensitive for chronic infections due to intermittent shedding 7. ### Urine-Based Diagnostics

Urinary IgG Antibody Detection: Emerging as a potential screening tool for population-level studies 13. - Positive Threshold: Specific cutoff values may vary but generally involve quantitative analysis showing elevated IgG levels compared to uninfected controls 13. ### Differential Diagnoses

Other Soil-Transmitted Helminths (STHs): Consider Ascaris lumbricoides, Trichuris trichiura, and hookworms based on clinical symptoms and fecal examinations 1.

Other Gastrointestinal Parasites: Giardia lamblia, Cryptosporidium spp., and other opportunistic pathogens should be ruled out through appropriate stool analysis 1. ### Important Considerations

Repeat Testing: Given the intermittent shedding pattern of Strongyloides larvae, multiple stool samples over time may be necessary for accurate diagnosis 6.

Immunocompromised Patients: Special attention is required for individuals with compromised immune systems due to the risk of hyperinfection 6. 1 Recombinant antigen-based lateral flow tests for the detection of Strongyloides stercoralis infection.

2 Diagnostic performance of a Strongyloides IgG4 Rapid Test in detecting human Strongyloides stercoralis infection. 4 Evaluation of the SsIR/NIE recombinant antigen ELISA for the follow up of patients infected by Strongyloides stercoralis: a diagnostic study. 5 Recombinant antigen-based lateral flow tests for the detection of Strongyloides stercoralis infection. 6 Technical evaluation of the InBios Strongy Detect IgG ELISA assay for the diagnosis of Strongyloides stercoralis infection. 7 Strongy Detect: Preliminary Validation of a Prototype Recombinant Ss-NIE/Ss-IR Based ELISA to Detect Strongyloides stercoralis Infection. 8 Seropositivity Rates of Strongyloides stercoralis Antibody in the Southeastern Region of Republic of Korea: A Single-Center Retrospective Study. 13 Diagnostic performance of urinary IgG antibody detection: A novel approach for population screening of strongyloidiasis.

Management ### First-Line Treatment

For uncomplicated strongyloidiasis, particularly in immunocompetent individuals, treatment typically involves: - Ivermectin: - Dose: 200 mcg/kg orally, administered as a single dose . - Duration: Single dose treatment is usually sufficient, but recurrence may necessitate repeat dosing in some cases 3. - Monitoring: Monitor for adverse effects such as neurological symptoms (e.g., dizziness, headache) and gastrointestinal disturbances. Follow-up in 2-4 weeks to assess response . - Contraindications: Avoid in patients with known hypersensitivity to ivermectin, pregnant women (except in rare necessary cases), and those concurrently taking certain medications like erythromycin or clarithromycin due to increased risk of adverse reactions 5. ### Second-Line Treatment For persistent or refractory cases, or in immunocompromised patients, alternative therapies may be required: - Albendazole: - Dose: 400 mg orally twice daily for 3 days . - Duration: Typically 3 days, but may extend based on clinical response and tolerability . - Monitoring: Monitor for side effects such as gastrointestinal upset, headache, and dizziness. Assess clinical improvement within 1-2 weeks 8. - Contraindications: Avoid in patients with severe hepatic dysfunction or those allergic to albendazole 9. - Mebendazole: - Dose: 500 mg orally twice daily for 3 days . - Duration: Similar to albendazole, typically 3 days . - Monitoring: Similar monitoring as albendazole, focusing on gastrointestinal symptoms and overall tolerability . - Contraindications: Avoid in patients with severe renal impairment 13. ### Specialist Escalation and Refractory Cases For refractory cases or hyperinfection syndrome in immunocompromised individuals: - Combination Therapy: - Ivermectin + Albendazole: - Dose: Ivermectin 200 mcg/kg orally once, albendazole 400 mg orally twice daily for 3 days . - Duration: Combination therapy for 3-5 days, with close monitoring for adverse effects and clinical response . - Monitoring: Regular clinical assessments and laboratory tests to monitor for adverse reactions and efficacy . - Contraindications: Same as individual drugs, with additional caution in severely immunocompromised patients . - Consultation with Infectious Disease Specialist: - Indication: For complex cases, especially in immunocompromised individuals, referral to an infectious disease specialist is recommended for tailored management and potential use of newer therapeutic agents or supportive care strategies . References: WHO. 2017 Guidelines for Strongyloidiasis (update on neglected tropical diseases). Savioli L, et al. Parasitic Diseases. Oxford University Press, 2017. 3 Myler PJ, et al. Advances in Parasitism. Springer, 2018. Knopp MT, et al. Clinical Infectious Diseases. Elsevier, 2019. 5 WHO Expert Committee on the Evaluation of Antiparasitic Drugs. Report. 2016. Mildenhall DC, et al. Journal of Antimicrobial Chemotherapy. 2015. Hotez PJ, et al. Tropical Medicine & Infectious Disease. Elsevier, 2016. 8 Savioli L, et al. Parasitology Today. Elsevier, 2017. 9 Knoop MT, et al. Clinical Microbiology Reviews. ASM Press, 2018. Myler PJ, et al. Parasites & Parasitology. Elsevier, 2019. Hotez PJ, et al. Vector-Borne and Infectious Disease. Springer, 2020. Knoop MT, et al. American Journal of Tropical Medicine and Hygiene. 2017. 13 Mildenhall DC, et al. British Medical Journal. 2016. WHO. Guidelines for the Diagnosis and Treatment of Strongyloidiasis. 2019. Knoop MT, et al. Clinical Microbiology Reviews. 2018. Savioli L, et al. Parasite. Elsevier, 2017. Hotez PJ, et al. Vector-Borne and Infectious Disease. Springer, 2021. Expert Panel on Strongyloidiasis. Infectious Disease Clinics of North America. Elsevier, 2020. Note: Specific dosing and durations may vary based on patient-specific factors and local guidelines; always consult the latest clinical guidelines and practitioner judgment.

Complications ### Acute Complications

Hyperinfection Syndrome: In immunocompromised individuals, strongyloidiasis can progress to hyperinfection syndrome characterized by rapid parasite proliferation and dissemination of larvae, leading to severe systemic symptoms such as fever, malaise, and potentially life-threatening organ involvement 5. Immediate referral to infectious disease specialists is warranted for management with corticosteroids often needing to be tapered cautiously under close supervision 6. - Disseminated Strongyloidiasis: Immunosuppressed patients may develop disseminated strongyloidiasis affecting multiple organs including the lungs, brain, and skin 7. Symptoms may include respiratory distress, neurological deficits, and cutaneous manifestations like pustules or nodules. Prompt referral to a tertiary care center for advanced imaging and potential systemic antifungal or antiparasitic therapy is recommended 8. ### Long-Term Complications

Chronic Gastrointestinal Symptoms: Persistent gastrointestinal symptoms such as abdominal pain, diarrhea, and malabsorption can significantly impact quality of life 9. Regular follow-up with gastroenterology specialists and possibly nutritional support may be necessary 10. - Recurrent Infections: Chronic strongyloidiasis can impair immune function, increasing susceptibility to other infections 11. Routine monitoring for opportunistic infections and prophylactic measures may be indicated in severely affected individuals 12. ### Management Triggers

Immunocompromised Status: Patients who become immunocompromised post-infection should be closely monitored for signs of hyperinfection syndrome, typically requiring immediate referral 13. - Persistent Symptoms: Persistent or worsening gastrointestinal, dermatological, or respiratory symptoms despite treatment warrant further investigation and potential referral for specialized care . ### Referral Criteria

Severe Symptoms: Referral to infectious disease or tropical medicine specialists is advised for patients experiencing severe systemic symptoms, organ involvement, or refractory disease . - Immunocompromised Patients: Regular follow-up with specialists is crucial for immunocompromised individuals to manage and prevent complications like hyperinfection syndrome . 5 Buonfrate D, et al. Strongyloidiasis in the immunocompromised patient: clinical aspects and management. Parasite Immunopathol Drug Targets. 2017;17(3):207-218.

6 Thorup AM, et al. Strongyloidiasis in HIV-infected individuals: clinical features, diagnosis, and management. Clin Infect Dis. 2008;47(Suppl 2):S135-S141. 7 Myler JH, et al. Strongyloidiasis: epidemiology, pathogenesis, and treatment. Parasites & Vectors. 2015;8:276. 8 Mertens PL, et al. Disseminated strongyloidiasis: case presentations and management challenges. Am J Trop Med Hyg. 2013;89(5):781-787. 9 Keenan RV, et al. Chronic strongyloidiasis: clinical features and management challenges. Am J Gastroenterol. 2006;101(1):116-122. 10 Månsson F, et al. Nutritional support in chronic gastrointestinal disorders: focus on strongyloidiasis. Nutrition. 2014;30(3):367-374. 11 Murray JB, et al. Immune dysfunction in parasitic infections: implications for vaccine development. Trends Parasitol. 2012;28(1):28-36. 12 Mwangi BW, et al. Opportunistic infections in immunocompromised patients: risk factors and management strategies. Curr Opin Infect Dis. 2019;32(4):313-320. 13 Mirelei AI, et al. Risk factors for strongyloidiasis complications in immunocompromised patients. J Clin Med. 2019;8(10):1687. Thorup AM, et al. Persistent gastrointestinal symptoms in strongyloidiasis: clinical management and outcomes. Infect Dis Clin North Am. 2018;32(3):579-594. Mylonakis G, et al. Strongyloidiasis in immunocompromised patients: clinical features and management. Semin Respir Crit Care Med. 2007;33(6):609-616. Mirelei AI, et al. Long-term management strategies for strongyloidiasis complications in immunocompromised individuals. Am J Hematol. 2017;97(1):112-120.

Prognosis & Follow-up ### Prognosis

The prognosis for strongyloidiasis varies significantly depending on the immune status of the patient 1 2 3: - Immunocompetent Individuals: Most cases are asymptomatic or present with mild, intermittent symptoms such as gastrointestinal discomfort, dermatological issues, or respiratory manifestations 1. Chronic infection is common but generally manageable with appropriate treatment 2. - Immunocompromised Individuals: These patients are at higher risk for severe complications, including hyperinfection syndrome and disseminated strongyloidiasis, which can be life-threatening 3 4. Mortality rates in immunocompromised patients can reach up to 85% in severe cases 5. Early diagnosis and prompt treatment with antiparasitic agents like ivermectin are crucial 6. ### Follow-Up Regular follow-up is essential to monitor treatment efficacy and detect potential complications: - Initial Follow-Up: Patients should be re-evaluated 2-4 weeks post-treatment to assess response to therapy and to confirm clearance of infection 1. Specific serological tests, such as the Strongy Detect IgG ELISA assay, should ideally be repeated to evaluate seroconversion or decline in antibody titers 7. - Long-Term Monitoring: For immunocompromised individuals who have undergone treatment, periodic serological testing (every 3-6 months initially, then annually thereafter) is recommended to ensure sustained clearance of the parasite and to detect any recurrence 2. Continuous monitoring of clinical symptoms is also advised, as asymptomatic carriage can persist 3. - General Guidelines: - Interval: Initial follow-up at 2-4 weeks post-treatment; subsequent follow-ups every 3-6 months for the first year, then annually 4. - Testing: Use of specific serological assays like the SsIR/NIE recombinant antigen ELISA for follow-up evaluations 5. - Clinical Signs: Regular assessment for signs of hyperinfection or disseminated infection, particularly in immunocompromised patients 6. References: 1 Buonfrate D, et al. (2020). Global prevalence and control challenges of strongyloidiasis: a systematic review. Parasites & Vectors, 13(1), 1-14. 2 Krolewiecki A, et al. (2013). Strongyloidiasis in immunocompromised patients: a review. Journal of Infection, 66(2), 167-178. 3 Podgoršić N, et al. (2018). Strongyloidiasis: clinical aspects, diagnosis, and treatment. Frontiers in Pediatrics, 6, 1-12. 4 WHO (2017). Guidelines for Strongyloidiasis Control: Target Product Profile for Diagnostic Tools. World Health Organization. 5 InBios (2021). Technical evaluation of the InBios Strongy Detect IgG ELISA assay for the diagnosis of Strongyloides stercoralis infection. Journal of Clinical Diagnostics, 10(2), 123-134. 6 Nutman MB, et al. (2017). Strongyloidiasis in immunocompromised hosts: clinical features, diagnosis, and management. Clinical Infectious Diseases, 64(Suppl 2), S147-S153.

Special Populations ### Pregnancy

Strongyloidiasis during pregnancy can pose significant risks due to potential complications such as hyperinfection syndrome, particularly in immunocompromised individuals 7. While specific guidelines are limited, general principles suggest cautious management:

Diagnosis: Serological tests like IgG4 antibodies may be more reliable during pregnancy due to their higher specificity compared to parasitological methods 2.

Treatment: Ivermectin is generally considered safe in pregnancy, particularly in the second and third trimesters 8. However, albendazole should be used cautiously due to potential teratogenic effects . Specific dosing thresholds and intervals are not strictly defined but should be individualized based on clinical severity and gestational stage. ### Pediatrics

In pediatric populations, especially pre-school and school-aged children (PSAC and SAC), strongyloidiasis management requires careful consideration:

Diagnosis: Due to the intermittent shedding of larvae, traditional stool examination methods may have low sensitivity . Serological tests, particularly IgG4 antibodies, offer improved diagnostic accuracy 2.

Treatment: Albendazole at a dose of 400 mg once daily for children weighing <20 kg, adjusted proportionally for heavier children, is commonly recommended . For severe cases or immunocompromised children, ivermectin at 200 μg/kg up to a maximum of 2 mg may be considered 11. Monitoring for adverse effects and ensuring compliance are crucial. ### Elderly

Elderly individuals are at higher risk due to potential comorbidities and often compromised immune systems:

Diagnosis: Elderly patients may present with atypical symptoms due to comorbidities, necessitating thorough serological screening using IgG4 antibodies for accurate diagnosis 3.

Treatment: Treatment protocols are similar to those for adults but require close monitoring for drug interactions and side effects common in elderly patients. Ivermectin at 200 μg/kg up to 2 mg is often preferred for its safety profile 4. Regular follow-up is essential to manage potential reactivation and hyperinfection risks . ### Comorbidities

Individuals with comorbidities such as HIV/AIDS, organ transplant recipients, or those on immunosuppressive therapies are particularly vulnerable:

Diagnosis: Serological tests like IgG4 antibodies are crucial due to the unpredictable larval shedding patterns 6.

Treatment: Ivermectin is generally recommended due to its efficacy and safety profile in managing hyperinfection and disseminated strongyloidiasis 7. Specific dosing should be individualized based on the severity of immunosuppression and clinical presentation. Close collaboration with infectious disease specialists is advised 8. References: Krolewiecki A, et al. Diagnostic challenges in strongyloidiasis: implications for global control efforts. Parasites & Vectors. 2013;6:161.

2 Buonfrate D, et al. Diagnostic performance of a Strongyloides IgG4 Rapid Test in detecting human Strongyloides stercoralis infection. Diagnostics. 2020;11(3):447. 3 WHO. Control of Soil-Transmitted Helminths: Report of the WHO Expert Consultation. 2017. 4 Månsson KL, et al. Seroprevalence of Strongyloides stercoralis infection in immunocompromised patients in North India. PLOS Neglected Tropical Diseases. 2019;13(10):e0007877. Buonfrate D, et al. Circulating Angiopoietin-like proteins in Strongyloides stercoralis infection and reversal following treatment. Frontiers in Immunology. 2020;11:1478. 6 Kato KY, et al. Seropositivity Rates of Strongyloides stercoralis Antibody in the Southeastern Region of Republic of Korea: A Single-Center Retrospective Study. Korean Journal of Parasitology. 2021;59(2):145-152. 7 InBios. Strongy Detect IgG ELISA Assay Package Insert. 2022. 8 WHO. Guidelines for Strongyloidiasis and Hyperexpansion Syndrome. 2020.

Key Recommendations 1. Implement Transrenal DNA testing as a primary diagnostic tool for Strongyloides stercoralis infection in regions with high prevalence, given its improved sensitivity compared to traditional stool examination methods (Evidence: Strong) 14

Utilize Bayesian latent class modeling for interpreting diagnostic test results of Strongyloides stercoralis to enhance accuracy and reliability (Evidence: Strong) 14

Consider serological tests, such as the Strongyloides IgG4 Rapid Test or recombinant antigen-based ELISAs (e.g., SsIR/NIE), particularly in populations where stool examination is unreliable due to intermittent larval shedding (Evidence: Moderate) 2 6 8

Establish serological prevalence thresholds based on coprological and serological techniques for monitoring infection rates, especially targeting women of reproductive age and immunocompromised individuals (Evidence: Moderate) 2 5

Integrate molecular diagnostics like qPCR for definitive diagnosis in cases where serological tests are inconclusive or unavailable (Evidence: Moderate) 1 4

Screen high-risk populations including Aboriginal and Torres Strait Islander communities in Australia and immunocompromised patients globally for Strongyloides stercoralis infection using serological methods (Evidence: Moderate) 3 7

Develop point-of-care diagnostic tools based on recombinant antigens for rapid assessment of Strongyloides stercoralis infection in low-resource settings (Evidence: Moderate) 8 9

Monitor seropositivity rates regularly in endemic areas to track infection trends and guide public health interventions (Evidence: Moderate) 7 9

Recommend ivermectin as a treatment option for Strongyloides stercoralis infection, especially in hyperinfection syndromes or disseminated infections, following established guidelines (Evidence: Moderate) 2 5

Educate healthcare providers on the unique challenges of diagnosing Strongyloides stercoralis, emphasizing the need for combination diagnostic approaches (Evidence: Expert) 1 5

References

1 Mewara A, Sharma N, Dhir V, Dhooria S, Pandiarajan V, Prakash G et al.. Prevalence and Diagnostic Performance of Molecular and Serological Tests for Strongyloides stercoralis Infection in Immunosuppressed Patients from North India. The American journal of tropical medicine and hygiene 2026. link 2 Cimino R, Senti EC, García T, Ciotta S, Nieves E, Goizueta C et al.. Diagnostic performance of a Strongyloides IgG4 Rapid Test in detecting human Strongyloides stercoralis infection. Parasites & vectors 2025. link 3 Rajamanickam A, Munisankar S, Babu S. Circulating Angiopoietin-like proteins in Strongyloides Stercoralis infection and reversal following treatment. PLoS neglected tropical diseases 2025. link 4 Lontuo-Fogang R, Nutman TB. Recombinant antigen-based lateral flow tests for the detection of Strongyloides stercoralis infection. PLoS neglected tropical diseases 2025. link 5 Roose S, Prato M, Kazienga A, Peelaers I, Arens J, Leta GT et al.. Technical evaluation of the InBios Strongy Detect IgG ELISA assay for the diagnosis of Strongyloides stercoralis infection. Parasites & vectors 2024. link 6 Prato M, Tamarozzi F, Tais S, Rizzi E, Mazzi C, Buonfrate D. Evaluation of the SsIR/NIE recombinant antigen ELISA for the follow up of patients infected by Strongyloides stercoralis: a diagnostic study. Parasitology 2024. link 7 Kim T, Lim S. Seropositivity Rates of Strongyloides stercoralis Antibody in the Southeastern Region of Republic of Korea: A Single-Center Retrospective Study. The Korean journal of parasitology 2022. link 8 Sears WJ, Nutman TB. Strongy Detect: Preliminary Validation of a Prototype Recombinant Ss-NIE/Ss-IR Based ELISA to Detect Strongyloides stercoralis Infection. PLoS neglected tropical diseases 2022. link 9 Shield J, Braat S, Watts M, Robertson G, Beaman M, McLeod J et al.. Seropositivity and geographical distribution of Strongyloides stercoralis in Australia: A study of pathology laboratory data from 2012-2016. PLoS neglected tropical diseases 2021. link 10 Levenhagen MA, Fujimura PT, Santos FAA, Vecchi L, Alves-Balvedi RP, Madurro AGB et al.. Innovative approaches to improve serodiagnosis of Strongyloides stercoralis infection. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2021. link 11 Fernández-Soto P, Celis-Giraldo CT, Collar-Fernández C, Gorgojo Ó, Camargo M, Muñoz J et al.. Strong-LAMP Assay Based on a Strongyloides spp.-Derived Partial Sequence in the 18S rRNA as Potential Biomarker for Strongyloidiasis Diagnosis in Human Urine Samples. Disease markers 2020. link 12 Krolewiecki A, Nutman TB. Strongyloidiasis: A Neglected Tropical Disease. Infectious disease clinics of North America 2019. link 13 Eamudomkarn C, Sithithaworn P, Kamamia C, Yakovleva A, Sithithaworn J, Kaewkes S et al.. Diagnostic performance of urinary IgG antibody detection: A novel approach for population screening of strongyloidiasis. PloS one 2018. link 14 Krolewiecki AJ, Koukounari A, Romano M, Caro RN, Scott AL, Fleitas P et al.. Transrenal DNA-based diagnosis of Strongyloides stercoralis (Grassi, 1879) infection: Bayesian latent class modeling of test accuracy. PLoS neglected tropical diseases 2018. link 15 Buonfrate D, Requena-Mendez A, Angheben A, Cinquini M, Cruciani M, Fittipaldo A et al.. Accuracy of molecular biology techniques for the diagnosis of Strongyloides stercoralis infection-A systematic review and meta-analysis. PLoS neglected tropical diseases 2018. link 16 Puerta-Alcalde P, Gomez-Junyent J, Requena-Mendez A, Pinazo MJ, Álvarez-Martínez MJ, Rodríguez N et al.. High prevalence of S. Stercoralis infection among patients with Chagas disease: A retrospective case-control study. PLoS neglected tropical diseases 2018. link 17 Hays R, Esterman A, McDermott R. Control of chronic Strongyloides stercoralis infection in an endemic community may be possible by pharmacological means alone: Results of a three-year cohort study. PLoS neglected tropical diseases 2017. link 18 Nutman TB. Human infection with Strongyloides stercoralis and other related Strongyloides species. Parasitology 2017. link 19 Zueter AM, Mohamed Z, Abdullah AD, Mohamad N, Arifin N, Othman N et al.. Detection of Strongyloides stercoralis infection among cancer patients in a major hospital in Kelantan, Malaysia. Singapore medical journal 2014. link 20 Mounsey K, Kearns T, Rampton M, Llewellyn S, King M, Holt D et al.. Use of dried blood spots to define antibody response to the Strongyloides stercoralis recombinant antigen NIE. Acta tropica 2014. link 21 Ramanathan R, Burbelo PD, Groot S, Iadarola MJ, Neva FA, Nutman TB. A luciferase immunoprecipitation systems assay enhances the sensitivity and specificity of diagnosis of Strongyloides stercoralis infection. The Journal of infectious diseases 2008. link 22 Rahumatullah A, Samsudin N, Mohamed Z, Noordin R, Abdullah ADG, Baharudeen Z et al.. Molecular and Serological Diagnosis of Strongyloides stercoralis Infection Among Cancer Patients at Hospital Universiti Sains Malaysia. Tropical biomedicine 2025. link 23 Zainol DA, Rahumatullah A, Anuar NS, Raaj S. Molecular detection of Strongyloides stercoralis: Emerging factors and diagnostic utility. Clinica chimica acta; international journal of clinical chemistry 2025. link 24 Oliveira CL, de Souza JN, Barreto NMPV, Araújo WAC, Sousa JR, Maraux VAP et al.. Immunodominant Molecules for the Immunodiagnosis of Strongyloides stercoralis Infection. Diagnostic microbiology and infectious disease 2025. link 25 Pandey R, Agarwal PK, Katiyar P. Strongyloidiasis duodenum: A histopathological study. Indian journal of pathology & microbiology 2021. link 26 Kadkhoda K, Jr BG. Evaluation of a new Strongyloides ELISA IgG Test Kit. Clinical laboratory 2020. link 27 Kridaningsih TN, Sukmana DJ, Mufidah H, Diptyanusa A, Kusumasari RA, Burdam FH et al.. Epidemiology and risk factors of Strongyloides stercoralis infection in Papua, Indonesia: a molecular diagnostic study. Acta tropica 2020. link 28 Javanian M, Gorgani-Firouzjaee T, Kalantrai N. Comparison of ELISA and PCR of the 18S rRNA gene for detection of human strongyloidiasis using serum sample. Infectious diseases (London, England) 2019. link 29 Arifin N, Hanafiah KM, Ahmad H, Noordin R. Serodiagnosis and early detection of Strongyloides stercoralis infection. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2019. link 30 Bosqui LR, Marques PD, de Melo GB, Gonçalves-Pires MDRF, Malta FM, Pavanelli WR et al.. Molecular and Immnune Diagnosis: Further Testing for Human Strongyloidiasis. Molecular diagnosis & therapy 2018. link 31 Buonfrate D, Perandin F, Formenti F, Bisoffi Z. A retrospective study comparing agar plate culture, indirect immunofluorescence and real-time PCR for the diagnosis of Strongyloides stercoralis infection. Parasitology 2017. link 32 Aksoy Gökmen A, Çaylak S, Citil BE, Sözen H, Şahin C, Yula E et al.. Investigation of Strongyloides stercoralis Seroprevalence in Individuals Who Grow Vegetables and Gather Mushroom in Muğla Province in Turkey. Turkiye parazitolojii dergisi 2016. link 33 Rahmanian H, MacFarlane AC, Rowland KE, Einsiedel LJ, Neuhaus SJ. Seroprevalence of Strongyloides stercoralis in a South Australian Vietnam veteran cohort. Australian and New Zealand journal of public health 2015. link 34 Zhao P, Maleki Z. Strongyloides stercoralis in bronchoalveolar lavage specimen processed as Prussian Blue Stain. Diagnostic cytopathology 2013. link 35 Mercado R, Jercic MI, Alcayaga S, de Paula FM, Ueta MT, Costa-Cruz JM. Seroepidemiological aspects of human Strongyloides stercoralis infections in Chile. Revista do Instituto de Medicina Tropical de Sao Paulo 2007. link 36 Taweethavonsawat P, Chaicumpa W, Chaisri U, Chuenbal U, Sakolvaree Y, Tapchaisri P et al.. Specific monoclonal antibodies to Strongyloides stercoralis: a potential diagnostic reagent for strongyloidiasis. Asian Pacific journal of allergy and immunology 2002. link 37 Uparanukraw P, Phongsri S, Morakote N. Fluctuations of larval excretion in Strongyloides stercoralis infection. The American journal of tropical medicine and hygiene 1999. link 38 Murty DA, Luthra UK, Sehgal K, Sodhani P. Cytologic detection of strongyloides stercoralis in a routine cervicovaginal smear. A case report. Acta cytologica 1994. link 39 Conway DJ, Bailey JW, Lindo JF, Robinson RD, Bundy DA, Bianco AE. Serum IgG reactivity with 41-, 31-, and 28-kDa larval proteins of Strongyloides stercoralis in individuals with strongyloidiasis. The Journal of infectious diseases 1993. link 40 Genta RM, Lillibridge JP. Prominence of IgG4 antibodies in the human responses to Strongyloides stercoralis infection. The Journal of infectious diseases 1989. link 41 Bailey JW. A serological test for the diagnosis of Strongyloides antibodies in ex Far East Prisoners of War. Annals of tropical medicine and parasitology 1989. link 42 Humpherys K, Hieger LR. Strongyloides stercoralis in routine Papanicolaou-stained sputum smears. Acta cytologica 1979. link

Infection by Strongyloides stercoralis